Inhibikase Therapeutics (IKT) Property, Plant & Equipment (Net) Growth (3y) (2025)
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Property, Plant & Equipment (Net) Growth (3y) (2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 14.05% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.65% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 411.50% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -3.34% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 16.78% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.66% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 19.96% |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - | - |